P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery

Advances in Pharmacology

Volumn 71, Issue , 2014, Pages 25-44

  Davis, Thomas P ^a   Sanchez Covarubias, Lucy ^a   Tome, Margaret E ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

ATP binding cassette transporter; Blood brain barrier; Drug delivery; Neurovascular unit; P glycoprotein; Peripheral inflammatory pain; Protein trafficking; Reactive oxygen species; Redox sensitive protein pools

Indexed keywords

CAVEOLIN 1; CENTRAL NERVOUS SYSTEM AGENTS; MULTIDRUG RESISTANCE PROTEIN; XENOBIOTIC AGENT; DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; DISULFIDE BOND; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; OXIDATION REDUCTION REACTION; PAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; PROTEIN TRANSPORT;

ANIMALS; BLOOD-BRAIN BARRIER; ENDOTHELIAL CELLS; HUMANS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PROTEIN TRANSPORT;

EID: 84907989747     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/bs.apha.2014.06.009     Document Type: Chapter

References (58)

1. Barakat S., Demeule M., Pilorget A., Regina A., Gingras D., Baggetto L.G., et al. Modulation of p-glycoprotein function by caveolin-1 phosphorylation. Journal of Neurochemistry 2007, 101:1-8.
2. Bendayan R., Lee G., Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microscopy Research and Technique 2002, 57:365-380.
3. Bendayan R., Ronaldson P.T., Gingras D., Bendayan M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. The Journal of Histochemistry and Cytochemistry 2006, 54:1159-1167.
4. Betz A.L., Firth J.A., Goldstein G.W. Polarity of the blood-brain barrier: Distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Research 1980, 192:17-28.
5. Cannon R.E., Peart J.C., Hawkins B.T., Campos C.R., Miller D.S. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:15930-15935.
6. Cartwright T.A., Campos C.R., Cannon R.E., Miller D.S. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers. Journal of Cerebral Blood Flow and Metabolism 2013, 33:381-388.
7. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-389.
8. Chen C., Pollack G.M. Extensive biliary excretion of the model opioid peptide [D-PEN2,5] enkephalin in rats. Pharmaceutical Research 1997, 14:345-350.
9. Chen C., Pollack G.M. Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. The Journal of Pharmacology and Experimental Therapeutics 1998, 287:545-552.
10. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. Journal of Clinical Investigation 2005, 115:3285-3290.
11. Demeule M., Regina A., Jodoin J., Laplante A., Dagenais C., Berthelet F., et al. Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascular Pharmacology 2002, 38:339-348.
12. Dohgu S., Yamauchi A., Takata F., Naito M., Tsuruo T., Higuchi S., et al. Transforming growth factor-beta1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cellular and Molecular Neurobiology 2004, 24:491-497.
13. Doran A., Obach R.S., Smith B.J., Hosea N.A., Becker S., Callegari E., et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metabolism and Disposition 2005, 33:165-174.
14. Goard C.A., Mather R.G., Vinepal B., Clendening J.W., Martirosyan A., Boutros P.C., et al. Differential interactions between statins and P-glycoprotein: Implications for exploiting statins as anticancer agents. International Journal of Cancer 2010, 127:2936-2948.
15. Golden P.L., Pardridge W.M. P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Research 1999, 819:143-146.
16. Gottesman M.M., Hrycyna C.A., Schoenlein P.V., Germann U.A., Pastan I. Genetic analysis of the multidrug transporter. Annual Review of Genetics 1995, 29:607-649.
17. Gribar J.J., Ramachandra M., Hrycyna C.A., Dey S., Ambudkar S.V. Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. The Journal of Membrane Biology 2000, 173:203-214.
18. Hartz A.M., Miller D.S., Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Molecular Pharmacology 2010, 77:715-723.
19. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacological Reviews 2005, 57:173-185.
20. Hawkins B.T., Rigor R.R., Miller D.S. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. Journal of Cerebral Blood Flow and Metabolism 2010, 30:1593-1597.
21. Ito S., Ohtsuki S., Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neuroscience Research 2006, 56:246-252.
22. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 1976, 455:152-162.
23. Largent-Milnes T.M., Yamamoto T., Nair P., Moulton J.W., Hruby V.J., Lai J., et al. Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. British Journal of Pharmacology 2010, 161:986-1001.
24. Lebrin F., Deckers M., Bertolino P., ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovascular Research 2005, 65:599-608.
25. Lee G., Dallas S., Hong M., Bendayan R. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacological Reviews 2001, 53:569-596.
26. Ling V., Thompson L.H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. Journal of Cellular Physiology 1974, 83:103-116.
27. Lochhead J.J., McCaffrey G., Quigley C.E., Finch J., Demarco K.M., Nametz N., et al. Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. Journal of Cerebral Blood Flow and Metabolism 2010, 30:1625-1636.
28. Lochhead J.J., McCaffrey G., Sanchez-Covarrubias L., Finch J.D., Demarco K.M., Quigley C.E., et al. Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain. American Journal of Physiology. Heart and Circulatory Physiology 2012, 302:H582-H593.
29. Loo T.W., Bartlett M.C., Clarke D.M. Human P-glycoprotein contains a greasy ball-and-socket joint at the second transmission interface. The Journal of Biological Chemistry 2013, 288:20326-20333.
30. McCaffrey G., Staatz W.D., Sanchez-Covarrubias L., Finch J.D., Demarco K., Laracuente M.L., et al. P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia. Journal of Neurochemistry 2012, 122:962-975.
31. Miller D.S., Bauer B., Hartz A.M. Modulation of P-glycoprotein at the blood-brain barrier: Opportunities to improve central nervous system pharmacotherapy. Pharmacological Reviews 2008, 60:196-209.
32. Oldendorf W.H., Cornford M.E., Brown W.J. The large apparent work capability of the blood-brain barrier: A study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Annals of Neurology 1977, 1:409-417.
33. Rao V.V., Dahlheimer J.L., Bardgett M.E., Snyder A.Z., Finch R.A., Sartorelli A.C., et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:3900-3905.
34. Rolfe D.F., Brown G.C. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiological Reviews 1997, 77:731-758.
35. Ronaldson P.T., Bendayan M., Gingras D., Piquette-Miller M., Bendayan R. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. Journal of Neurochemistry 2004, 89:788-800.
36. Ronaldson P.T., Davis T.P. Targeted drug delivery to treat pain and cerebral hypoxia. Pharmacological Reviews 2013, 65:291-314.
37. Ronaldson P.T., Demarco K.M., Sanchez-Covarrubias L., Solinsky C.M., Davis T.P. Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. Journal of Cerebral Blood Flow and Metabolism 2009, 29:1084-1098.
38. Ronaldson P.T., Finch J.D., Demarco K.M., Quigley C.E., Davis T.P. Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier. The Journal of Pharmacology and Experimental Therapeutics 2011, 336:827-839.
39. Roninson I.B., Chin J.E., Choi K.G., Gros P., Housman D.E., Fojo A., et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:4538-4542.
40. Sanchez del Pino M.M., Peterson D.R., Hawkins R.A. Neutral amino acid transport characterization of isolated luminal and abluminal membranes of the blood-brain barrier. The Journal of Biological Chemistry 1995, 270:14913-14918.
41. Sanchez-Covarrubias L., Slosky L.M., Thompson B.J., Davis T.P., Ronaldson P.T. Transporters at CNS barrier sites: Obstacles or opportunities for drug delivery?. Current Pharmaceutical Design 2014, 20:1422-1449.
42. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
43. Schlachetzki F., Pardridge W.M. P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. Neuroreport 2003, 14:2041-2046.
44. Seelbach M.J., Brooks T.A., Egleton R.D., Davis T.P. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: A role for P-glycoprotein. Journal of Neurochemistry 2007, 102:1677-1690.
45. Sharom F.J. Multidrug resistance protein: P-glycoprotein. Drug transporters: Molecular characterization and role in drug disposition 2007, 263-318. John Wiley & Sons, Hoboken, NJ. G. You, M.E. Morris (Eds.).
46. Shirasaka Y., Suzuki K., Nakanishi T., Tamai I. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. Journal of Pharmaceutical Sciences 2011, 100:3843-3853.
47. Shirasaka Y., Suzuki K., Shichiri M., Nakanishi T., Tamai I. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metabolism and Pharmacokinetics 2011, 26:171-179.
48. Smit J.J., Schinkel A.H., Oude Elferink R.P., Groen A.K., Wagenaar E., van Deemter L., et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75:451-462.
49. Spudich A., Kilic E., Xing H., Kilic U., Rentsch K.M., Wunderli-Allenspach H., et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nature Neuroscience 2006, 9:487-488.
50. Sun J., He Z.G., Cheng G., Wang S.J., Hao X.H., Zou M.J. Multidrug resistance P-glycoprotein: Crucial significance in drug disposition and interaction. Medical Science Monitor 2004, 10:RA5-RA14.
51. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
52. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:3004-3008.
53. van Assema D.M., Lubberink M., Bauer M., van der Flier W.M., Schuit R.C., Windhorst A.D., et al. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 2012, 135:181-189.
54. Volk H.A., Burkhardt K., Potschka H., Chen J., Becker A., Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004, 123:751-759.
55. Vorbrodt A.W., Dobrogowska D.H. Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: Electron microscopist's view. Brain Research. Brain Research Reviews 2003, 42:221-242.
56. Xie Y., Burcu M., Linn D.E., Qiu Y., Baer M.R. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Molecular Pharmacology 2010, 78:310-318.
57. Yamamoto T., Nair P., Jacobsen N.E., Vagner J., Kulkarni V., Davis P., et al. Improving metabolic stability by glycosylation: Bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists. Journal of Medicinal Chemistry 2009, 52:5164-5175.
58. Zhang C., Kwan P., Zuo Z., Baum L. The transport of antiepileptic drugs by P-glycoprotein. Advanced Drug Delivery Reviews 2012, 64:930-942.